8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
May 6, 2026·SEC
Actuate Therapeutics Inc(ACTU)Earnings, Financials & Key Ratios
ACTU•NASDAQ
$1.40
Price updated Jul 6, 2026
AboutActuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Show more
- Revenue$0
- EBITDA-$22M+2.3%
- Net Income-$22M+18.5%
- EPS (Diluted)-1.06+67.5%
- ROE-553.75%+97.9%
ACTU Price & Volume
Actuate Therapeutics Inc (ACTU) stock price & volume — 10-year historical chart
Loading chart...
ACTU Growth Metrics
Actuate Therapeutics Inc (ACTU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.3%
Return on Capital
10 Years-1479.87%
5 Years-1479.87%
3 Years-1931.42%
Last Year-508.66%
Peers Comparison
Key metrics vs top competitors for Actuate Therapeutics Inc (ACTU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.40 | $33.5M | -1.32 | — | — | -553.75% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $4.79 | $194.47M | 3.93 | 36.55% | -19.55% | -3.39% | — | |
| $37.39 | $2.22B | -5.25 | 48.03% | -639.84% | -34.11% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $39.37 | $3.46B | -30.76 | 3024.43% | -62.17% | -13.96% | — |
Compare ACTU vs Peers
Actuate Therapeutics Inc (ACTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACTU SEC Filings & Documents
Actuate Therapeutics Inc (ACTU) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ACTU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACTU Frequently Asked Questions
Actuate Therapeutics Inc (ACTU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ACTU profitable?
Actuate Therapeutics Inc (ACTU) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
What is ACTU's return on equity?
Actuate Therapeutics Inc (ACTU) has a return on equity (ROE) of -553.7%. Negative ROE indicates the company is unprofitable.
What is Actuate Therapeutics Inc's free cash flow?
Actuate Therapeutics Inc (ACTU) had negative free cash flow of $19.8M in fiscal year 2025, likely due to heavy capital investments.